Search the Newsreel

Die Edwards-Lifesciences-Aktie steigt dank starker Q2-Dynamik und hoher Bewertung

TMC Life Sciences Berhad Declares First and Final Single-Tier Dividend in Respect of the Financial Year Ended 30 June 2026

Gilead wins appeals court ruling against overseas drug imports

A federal appeals court has upheld a preliminary injunction preventing companies from importing international versions of Gilead's HIV drug Biktarvy into the U.S. and distributing them via employer health plans. The court ruled that the overseas versions materially differ from FDA-regulated U.S. versions, highlighting …

Aarvi Encon net profit up 43% in Q1FY27; EBITDA margin slips to 2.61%

Is Cadence Worth Buying as AI Growth Collides With Premium Valuation?

Cadence Design Systems (CDNS) is experiencing strong growth due to increasing AI-related demand, with rising earnings expectations and robust cash generation. Despite its solid growth prospects and continued expansion in revenues and earnings, the stock trades at a significant premium valuation compared to its …

Cadence Raises 2026 Outlook as AI Agents Drive Broader EDA Demand

Cadence Design Systems (CDNS) has raised its 2026 financial outlook, driven by strong second-quarter results and expanding AI-oriented demand across its portfolio. The company reported significant growth in all product groups, with backlog reaching a record $8.1 billion, and sees agentic AI as a …

CDNS Falls 12.9% in the Past Month. Is the Sell-Off an Opportunity?

Cadence Design Systems (CDNS) shares have dropped 12.9% in the past month despite strong Q2 revenue and earnings growth, leading to a compressed valuation. While the stock's valuation is now at the lower end of its five-year range, it still trades at a premium …

Daré Bioscience Announces $6.0 Million Registered Direct Offering and Concurrent Private Placement

Daré Bioscience has announced a definitive securities purchase agreement with institutional investors for a registered direct offering, expecting to raise approximately $6.0 million. The offering includes the sale of about 4.38 million shares of common stock at $1.37 per share, along with concurrent private …

Highbridge Capital (AXIN) discloses 9.1% holding in Axiom Intelligence Class A

Kodiak Sciences (NASDAQ:KOD) Shares Gap Down - Time to Sell?

Kodiak Sciences (NASDAQ:KOD) shares gapped down before Friday's market open, though they later recovered some ground. The clinical-stage biopharmaceutical company, which focuses on retinal disease treatments, reported a quarterly loss that missed analyst estimates. Despite the earnings miss, analyst sentiment is generally positive, with …

Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $8

Citi has reiterated its Buy rating for Caribou Biosciences (CRBU.US) and maintained its target price at $8. This indicates the firm's continued positive outlook on the company's stock performance.

Cellectar Biosciences (CLRB) investor discloses 9.99% stake and warrant holdings

SilverArc Capital Management, LLC and Devesh Gandhi have reported a beneficial ownership of 9.99% in Cellectar Biosciences Inc. Class A Common Stock, totaling 851,285 shares. This disclosure, made via a SCHEDULE 13G SEC filing, indicates shared voting and dispositive power over these shares. The …

Twist Bioscience (NASDAQ:TWST) Trading Down 4.3% - Here's What Happened

Kingfa Science & Technology Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Aytu BioPharma (AYTU) investor and foundation each report 4.99% beneficial stake

An investor, Laurence W. Lytton, and the Lytton-Kambara Foundation have each reported a 4.99% beneficial ownership stake in Aytu BioPharma (AYTU), according to a recent Schedule 13G/A filing. Each party beneficially owns 545,946 shares, consisting of common stock and warrants, with all voting and …

Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?

Edwards Lifesciences Corporation EW is entering the second half of 2026 with faster structural heart growth and better operating leverage. Second-quarter revenues rose 13.6% to $1.74 billion, while adjusted earnings increased 16.4% to 78 cents per share. The question is whether that momentum warrants …

Inhibrx Biosciences (NASDAQ:INBX) Shares Gap Down After Earnings Miss

Inhibrx Biosciences (NASDAQ:INBX) experienced a share price drop after missing earnings estimates, opening at $91.80, down from its previous close of $97.01. The company reported an EPS of $(2.34) against an estimated $(2.28). Analyst ratings for INBX are mixed, with an average "Hold" rating …

TuHURA Biosciences, Inc. - Common Stock (HURA) Stock Price, News, Quote & History

This article provides a comprehensive overview of TuHURA Biosciences, Inc. (HURA) stock, including its current price, market data, and recent news. It highlights the company's focus on advancing biotechnology solutions, particularly in developing therapies and diagnostic tools. The news section features updates on their …

Armistice Capital (RKDA holder) discloses 9.99% beneficial stake in Arcadia Biosciences

Armistice Capital, LLC and Steven Boyd have reported a 9.99% beneficial ownership stake in Arcadia Biosciences, Inc., totaling 267,392 shares. These shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital acting as the investment manager, exercising shared voting and dispositive power. …

Form 8K Skye Bioscience Inc For: 14 August By Investing.com

This article reports that Skye Bioscience Inc. filed a Form 8K on August 14. The filing is a standard disclosure document used by public companies to announce major events that shareholders should know about. The article provides no further details on the content of …

TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord

TuHURA Biosciences presented its late-stage immuno-oncology pipeline at the Canaccord Genuity Growth Conference, detailing a Phase III study of IFx in Merkel cell carcinoma, a planned AML trial for its VISTA-inhibiting antibody, and preclinical work on immune-modulating antibody-drug conjugates. The company aims to address …

Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $37.56, Implies 16% Upside

Alto Neuroscience, Inc. (ANRO) has seen its average 12-month price target increased to $37.56 by 9 analysts, suggesting a 16% potential upside from its August 13 closing price. The consensus rating for the stock remains a "Buy" from 11 analysts.

GUFICBIO: Q1 FY27 saw strong profit growth and a major international expansion into the Philippines

Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline

Harmony Biosciences reported record quarterly growth for its narcolepsy treatment WAKIX, which supports further investment in its pipeline. The company is advancing BP-205, an orexin 2 receptor agonist, with promising early data and plans for multiple Phase II studies. Additionally, Harmony is progressing Phase …

TuHURA Biosciences Q2 Results: EPS beats estimate, losses narrow 33% YoY

Promis Neurosciences (NASDAQ:PMN) Stock Price Expected to Rise, Guggenheim Analyst Says

Guggenheim raised its price target for Promis Neurosciences (NASDAQ:PMN) from $69 to $100, maintaining a "Buy" rating, while other analysts have varied ratings but a consensus "Moderate Buy" with a $39.25 target. The clinical-stage biopharmaceutical company's shares opened at $14.93, with a market capitalization …

ProMIS Neurosciences Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 195% Upside

ProMIS Neurosciences Inc. (PMN) has seen its 12-month average price target raised by analysts from $39.21 to $43.64, with forecasts ranging from $18 to $100 per share. This new target suggests a potential upside of approximately 195% based on the August 13 closing price. …

Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus

Kodiak Sciences reported a wider-than-expected Q2 2026 loss of $1.05 per share, surpassing the Zacks Consensus Estimate of a 97-cent loss. Despite increased R&D expenses for pipeline development, the company's cash position is expected to sustain operations into 2027. Kodiak is accelerating regulatory submissions …

Encore Capital Group stock hits all-time high at 102.64 USD

Encore Capital Group (ECPG) stock has reached an all-time high of $102.64, demonstrating a 149.67% increase over the past year. The company's P/E ratio is 7.63, and analysts have set price targets between $112-$120. This positive momentum is further supported by recent Q2 2026 …

Caribou Biosciences, Inc. Stock 12‑Month Price Target Cut to $11.86, Implies 636% Upside

Analysts have cut the 12-month average price target for Caribou Biosciences, Inc. stock from $12 to $11.86, with individual forecasts ranging from $4 to $32 per share. Despite the slight reduction in the average target, this still implies a significant 636% potential upside based …

T. Rowe Price Associates (EHC) discloses 5.1% Encompass Health stake on Schedule 13G

T. Rowe Price Associates has filed a Schedule 13G, disclosing a 5.1% beneficial ownership stake in Encompass Health Corp (EHC), totaling 5,056,225 common stock shares. The filing indicates that T. Rowe Price Associates holds sole voting power over 4,897,333 shares and sole dispositive power …

Alamar Biosciences (ALMR) Stock Price Jumps As Margin Gains Meet Loss Pressure

Alamar Biosciences (ALMR) stock surged 30.7% after its first post-IPO quarter, despite reporting a net loss of US$13.2m. The company achieved US$29.4m in revenue and a record 60% gross margin, driven by strong demand for consumables and instruments. While bulls highlight top-line growth and …

Skye Bioscience to Acquire Redx; Secures $67.9M Financing and $22M Equity Line

Skye Bioscience is set to acquire Redx through a UK court-sanctioned scheme of arrangement, backed by a significant financing package. The deal includes a $67.9 million equity financing (potentially rising to $72.9 million), a $22.0 million equity line, and a $5.0 million warrant with …

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Skye Bioscience and Redx Pharma have announced a definitive transaction agreement, forming a combined company named Fibrx Therapeutics, which will focus on developing novel small molecule medicines for fibrotic diseases. This merger is supported by approximately $125 million in financings, including a PIPE financing …

enCore Energy (NASDAQ:EU) Given New $3.50 Price Target at HC Wainwright

HC Wainwright has lowered its price target for enCore Energy (NASDAQ:EU) to $3.50 from $3.75 but maintained a "buy" rating, indicating a potential upside of 207% from its current price. Despite this, the company has a consensus "hold" rating from analysts, and its recent …

Forte Biosciences earnings on deck as $2.2 billion argenx deal nears

Forte Biosciences is set to report its second-quarter earnings, which are expected to be largely a formality as the company awaits the completion of its $2.2 billion acquisition by argenx. Analysts anticipate a loss of $1.01 per share on zero revenue for Forte. The …